Sonoma Biotherapeutics launches with $40 million in Series A funding to advance regulatory T cell therapy in autoimmune and degenerative diseases

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2SqaB8M
via IFTTT